Switch Study of Existing Atypical Antipsychotics to Bifeprunox - Full Text View

Sponsors and Collaborators:	Solvay Pharmaceuticals H. Lundbeck A/S Wyeth
Information provided by:	Solvay Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00347425

Purpose

The study will evaluate the safety and tolerability of switching subjects with schizophrenia or schizoaffective disorder from their existing antipsychotic medication to Bifeprunox.

Condition	Intervention	Phase
Schizophrenia and Schizoaffective Disorder	Drug: Aripiprazole Drug: Olanzapine Drug: Risperidone Drug: Quetiapine Drug: Ziprasidone	Phase III

MedlinePlus related topics: Psychotic Disorders Schizophrenia

Drug Information available for: Risperidone Quetiapine Quetiapine fumarate Ziprasidone hydrochloride Aripiprazole Olanzapine Ziprasidone Ziprasidone mesylate Bifeprunox Bifeprunox mesylate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Multicenter, Open-Label, Parallel-Group, Randomized, Flexible Dose Study To Evaluate the Safety and Tolerability of Switching From Existing Atypical Antipsychotics to Bifeprunox in Subjects With Schizophrenia or Schizoaffective Disorder

Further study details as provided by Solvay Pharmaceuticals:

Primary Outcome Measures:

Successful switch defined as those who complete the 4 weeks core study with no worsening of 2 successive post baseline assessments on the CGIS, exacerbation of EPS, or cardiovascular risk factors (body weight and fasting triglycerides) from baseline. [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Adverse events [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
Adverse events [ Time Frame: 26 weeks ] [ Designated as safety issue: Yes ]

Enrollment:	286
Study Start Date:	December 2006
Study Completion Date:	February 2008
Primary Completion Date:	February 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
A	Drug: Aripiprazole Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox Drug: Olanzapine Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox Drug: Risperidone Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox Drug: Quetiapine Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox Drug: Ziprasidone Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
B	Drug: Aripiprazole Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days Drug: Olanzapine Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days Drug: Risperidone Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days Drug: Quetiapine Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days Drug: Ziprasidone Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days

Arms

Assigned Interventions

A

Drug: Aripiprazole